Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism.

Maeda DY, Quinn MT, Schepetkin IA, Kirpotina LN, Zebala JA.

J Pharmacol Exp Ther. 2010 Jan;332(1):145-52. doi: 10.1124/jpet.109.159020. Epub 2009 Sep 24.

2.

Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.

Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW.

J Pharmacol Exp Ther. 2007 Aug;322(2):477-85. Epub 2007 May 11.

3.

Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.

Maeda DY, Peck AM, Schuler AD, Quinn MT, Kirpotina LN, Wicomb WN, Fan GH, Zebala JA.

J Med Chem. 2014 Oct 23;57(20):8378-97. doi: 10.1021/jm500827t. Epub 2014 Oct 8.

4.

Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.

Kaur M, Singh D.

J Pharmacol Exp Ther. 2013 Oct;347(1):173-80. doi: 10.1124/jpet.112.201855. Epub 2013 Aug 2.

5.

Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.

Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD.

Pulm Pharmacol Ther. 2015 Oct;34:37-45. doi: 10.1016/j.pupt.2015.08.002. Epub 2015 Aug 10. Review.

PMID:
26271598
6.

Nicotinamide N-oxides as CXCR2 antagonists.

Cutshall NS, Ursino R, Kucera KA, Latham J, Ihle NC.

Bioorg Med Chem Lett. 2001 Jul 23;11(14):1951-4.

PMID:
11459668
7.

Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.

Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Mårdh CK.

J Pharmacol Exp Ther. 2015 May;353(2):340-50. doi: 10.1124/jpet.114.221358. Epub 2015 Mar 3.

8.

CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1.

Braber S, Overbeek SA, Koelink PJ, Henricks PA, Zaman GJ, Garssen J, Kraneveld AD, Folkerts G.

Eur J Pharmacol. 2011 Oct 15;668(3):443-9. doi: 10.1016/j.ejphar.2011.03.025. Epub 2011 Mar 31.

PMID:
21458445
9.

A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist.

Nicholson GC, Tennant RC, Carpenter DC, Sarau HM, Kon OM, Barnes PJ, Salmon M, Vessey RS, Tal-Singer R, Hansel TT.

Pulm Pharmacol Ther. 2007;20(1):52-9. Epub 2006 Jan 6.

PMID:
16406722
10.

Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8((3-74))K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology.

Zhao X, Li F, Town JR, Zhang X, Wang W, Gordon JR.

Int Immunopharmacol. 2007 Dec 15;7(13):1723-31. Epub 2007 Sep 29.

PMID:
17996682
11.

The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-alpha-PGP) does not interact directly with human CXCR1 and CXCR2.

de Kruijf P, Lim HD, Overbeek SA, Zaman GJ, Kraneveld AD, Folkerts G, Leurs R, Smit MJ.

Eur J Pharmacol. 2010 Sep 15;643(1):29-33. doi: 10.1016/j.ejphar.2010.06.017. Epub 2010 Jun 21.

PMID:
20599927
12.

Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.

Catusse J, Struyf S, Wuyts A, Weyler M, Loos T, Gijsbers K, Gouwy M, Proost P, Van Damme J.

Biochem Pharmacol. 2004 Nov 15;68(10):1947-55.

PMID:
15476666
13.

Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils.

Zhang Z, Cherryholmes G, Chang F, Rose DM, Schraufstatter I, Shively JE.

Eur J Immunol. 2009 Nov;39(11):3181-94. doi: 10.1002/eji.200939496.

14.

Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.

Widdowson KL, Elliott JD, Veber DF, Nie H, Rutledge MC, McCleland BW, Xiang JN, Jurewicz AJ, Hertzberg RP, Foley JJ, Griswold DE, Martin L, Lee JM, White JR, Sarau HM.

J Med Chem. 2004 Mar 11;47(6):1319-21.

PMID:
14998320
15.

Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model.

Maeda DY, Peck AM, Schuler AD, Quinn MT, Kirpotina LN, Wicomb WN, Auten RL, Gundla R, Zebala JA.

Bioorg Med Chem Lett. 2015 Jun 1;25(11):2280-4. doi: 10.1016/j.bmcl.2015.04.041. Epub 2015 Apr 23.

16.

Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice.

Cunha TM, Barsante MM, Guerrero AT, Verri WA Jr, Ferreira SH, Coelho FM, Bertini R, Di Giacinto C, Allegretti M, Cunha FQ, Teixeira MM.

Br J Pharmacol. 2008 May;154(2):460-70. doi: 10.1038/bjp.2008.94. Epub 2008 Mar 24.

17.

CXCR2 stimulation primes CXCR1 [Ca2+]i responses to IL-8 in human neutrophils.

Hauser CJ, Fekete Z, Goodman ER, Kleinstein E, Livingston DH, Deitch EA.

Shock. 1999 Dec;12(6):428-37.

PMID:
10588510
18.

Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils.

Strandberg K, Blidberg K, Sahlander K, Palmberg L, Larsson K.

Pulm Pharmacol Ther. 2010 Aug;23(4):316-23. doi: 10.1016/j.pupt.2010.03.004. Epub 2010 Mar 20.

PMID:
20307681
19.

LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.

Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D.

Int Immunopharmacol. 2012 Jul;13(3):225-31. doi: 10.1016/j.intimp.2012.04.008. Epub 2012 May 2.

PMID:
22561413
20.

The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.

Gordon JR, Li F, Zhang X, Wang W, Zhao X, Nayyar A.

J Leukoc Biol. 2005 Dec;78(6):1265-72. Epub 2005 Oct 4.

PMID:
16204619

Supplemental Content

Support Center